Mymetics announces successful preclinical results with malaria transmission-blocking vaccine candidate
Epalinges, Switzerland, 5 April 2016
Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome based vaccines to prevent transmission of human infectious diseases, announced today that the preclinical study with Mymetics’ virosome based formulations for a malaria transmission-blocking vaccine candidate has been successful. The study showed that the virosome vaccine candidates, at the highest dose tested, generate high antibody titers against the required antigens and they were able to significantly reduce (97-100%) the transmission of the Plasmodium falciparum parasite.
|Media Name||Media Type||Description||Download|
|160404_Malaria press release||Download|